aTYR PHARMA ATYR Insider Ownership

Updated Oct 10, 2026

Across the past 12 months, open-market trades by aTYR Pharma insiders totaled $49,630 in purchases (100K shares) and $6,267 in sales (6.42K shares).

• Counted by insider, open-market buying of ATYR stock in the past 12 months came from one insider and selling from 3 insiders.
• Among aTYR Pharma's insiders, the largest open-market purchases in the past 12 months were by Paul Schimmel (Director), totaling $49,630 (100K shares), most recently on May 27, 2026.
• Conversely, Sanjay Shukla (President and CEO) was ATYR's largest open-market seller in the past 12 months, with $3,655 of sales (3.75K shares); the latest was on February 4, 2026.
• Beyond open-market trades, insiders at aTYR Pharma acquired 16.81K shares through option exercises and conversions in the last 12 months.
• Per Business Quant, ATYR insiders together hold 2.5Mn shares based on their latest Form 4 filings, unchanged from 2.5Mn shares at the end of Q2 2026 and up 78.28% from 1.4Mn shares at the end of Q3 2025.
• By type of ownership, ATYR insiders hold 10.17% of their shares directly (254.61K shares) and 89.83% indirectly (2.25Mn shares).
• ATYR's insider total is spread across 8 insiders who have filed a Form 4 in the past two years.
• ATYR's largest insider holders by reported holdings are Paul Schimmel (Director, 2.2Mn shares), Sanjay Shukla (President and CEO, 153.55K shares) and Timothy Coughlin (Director, 56K shares).
• Of the shares held by ATYR insiders, 87.94% belong to Paul Schimmel.
• Institutional holders reported 39.80% of aTYR Pharma's outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 2.55%, and other investors, including the public, hold the remaining 57.65%.
• Over the past 12 months, 10 insiders reported transactions in aTYR Pharma stock in 14 Form 4 filings.
• This summary of aTYR Pharma insider activity covers Form 4 filings through October 1, 2026.